EFPIA objects to ‘pressure’ from EMA over theoretical medicines shortages
This article was originally published in Scrip
EFPIA, the federation of R&D-based industry associations, is using concern about the impact of forthcoming legislation on drug shortages to call for the European Medicines Agency to look more closely the impact of low prices. EFPIA is warning the agency that it must find a pragmatic way to implement the highly problematic Falsified Medicines Directive.
You may also be interested in...
Biogen has described as “exciting” a first-of-a-kind interim data review that has led to expanded recommendations for the company’s spinal muscular atrophy drug Spinraza.
Artificial intelligence can facilitate outcomes agreements and help companies make their value proposition to health technology assessment bodies.
After arbitrators set an unpalatably low price for the company, bluebird is withdrawing its Zyntgelo gene therapy from Germany. The company also announced it would be restructuring its workforce, with job losses expected.